84-3348-79　［取扱停止］Nuclear Receptor Rev-ErbA alpha (Rev ErbA alpha, Rev-ErbA-alpha, Rev Erb alpha, Rev-Erb-alpha, Rev-erbalpha, Rev-ErbA, ErbA-related 1, EAR1, EAR-1, hRev, Nuclear Receptor Subfamily 1 Group D Member 1, NR1D1, Orphan Nuclear Receptor NR1D1, THRA1, Thyroid Hormone Receptor alpha-like, THRAL, V-erbA-related Protein EAR-1, V-erbA Related Protein EAR-1) (AP) 100ul　N6889-85G-AP

特徴

• Rev-ErbA alpha (NR1D1 or nuclear receptor subfamily 1, group D, member 1), is a member of the Rev-ErbA family of nuclear receptors and is a transcriptional repressor.
• In mammals, Rev-Erba is highly expressed in the liver, skeletal muscle, adipose tissue, and the brain, participating in the development and circadian regulation of these tissues.
• Rev-Erba regulates gene transcription by directly binding to target response elements (RevREs), comprises an A/T-rich flank followed by AGGTCA.
• Rev-Erba mediates repression by recruiting the corepressor N-CoR, which then activates the histone deacetylase (HDAC) 3.
• A number of target genes has been identified for Rev-Erba, including the lipoproteins ApoA1 and ApoCIII, hydratase dehydrogenase, the circadian factor BMAL, and the anti-fibrinolytic factor PAI-1.
• Many of these genes are coordinately regulated by Rev-erba and the RAR-related orphan receptor RORa, which share the same response elements but exert opposite effects on gene transcription.
• Crosstalk between Rev-Erba and RORa likely acts to fine-tune of their target physiologic networks, such as circadian rhythms, metabolic homeostasis, and inflammation.
• Applications:Suitable for use in Western Blot.
• Other applications not tested.
• Recommended Dilution:Western Blot: 1ug/mlOptimal dilutions to be determined by the researcher.
• Positive Control:A431 cell lysate
• Storage and Stability:Store product at 4°C.
• DO NOT FREEZE! Stable at 4°C for 12 months after receipt as an undiluted liquid.
• Dilute required amount only prior to immediate use.
• Further dilutions can be made in assay buffer.
• For maximum recovery of product, centrifuge the original vial prior to removing the cap.
• Note: Applications are based on unconjugated antibody.